Stay updated on Trastuzumab Emtansine in Chinese HER2+ Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the Trastuzumab Emtansine in Chinese HER2+ Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Trastuzumab Emtansine in Chinese HER2+ Breast Cancer Clinical Trial page

  1. Check
    6 days ago
    No Change Detected
  2. Check
    13 days ago
    Change Detected
    Summary
    The update shows Revision: v3.4.2 replacing v3.4.1, which appears to be a minor version revision without changes to study content, eligibility, locations, or outcomes. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2026-02-12T02:51:56.000Z thumbnail image
  3. Check
    20 days ago
    Change Detected
    Summary
    Revision updated from v3.4.0 to v3.4.1; a minor update that does not affect study data or user interactions. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2026-02-04T22:33:28.000Z thumbnail image
  4. Check
    27 days ago
    Change Detected
    Summary
    The page now shows a glossary and metadata labels have been updated to Last Update Submitted that Met QC Criteria, No FEAR Act Data, and Revision: v3.4.0, replacing the previous Last Update Submitted that met QC Criteria, No FEAR Act data, and Revision: v3.3.4.
    Difference
    0.2%
    Check dated 2026-01-28T20:02:49.000Z thumbnail image
  5. Check
    42 days ago
    Change Detected
    Summary
    The page revision updated from v3.3.3 to v3.3.4, which appears to be a minor backend/format update without changes to the study content or outcomes. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2026-01-14T03:44:26.000Z thumbnail image
  6. Check
    63 days ago
    Change Detected
    Summary
    Footer updates show a new Revision: v3.3.3 and removal of HHS Vulnerability Disclosure and Revision: v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2025-12-23T21:20:58.000Z thumbnail image
  7. Check
    91 days ago
    Change Detected
    Summary
    Publication notes were updated: a new line clarifies that PubMed-sourced publications may or may not relate to the study, and a revision tag 'Revision: v3.3.2' was added. The older, longer description stating PubMed publications are automatically created by ClinicalTrials.gov and tied to the NCT number was removed.
    Difference
    0.1%
    Check dated 2025-11-25T11:00:38.000Z thumbnail image

Stay in the know with updates to Trastuzumab Emtansine in Chinese HER2+ Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Trastuzumab Emtansine in Chinese HER2+ Breast Cancer Clinical Trial page.